Back

What is the benefit risk ratio of combination therapy?

2 September 2014 (13:15 - 13:30)
Organised by:
Part of: Combination therapy in dyslipidaemia. What is new in Europe? Epidemiology, lipids ESC CONGRESS 2014

Slides

About the speaker

Photo
Doctor Carlos Aguiar

Hospital Santa Cruz, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Introduction - Combination therapy in dyslipidaemia. What is new in Europe?
Slides
Presentation thumbnail
What is atherogenic dyslipidaemia? Does it really exist?
Professor M. Krempf (Nantes, FR)
Slides
Presentation thumbnail
Is LDL-C lowering treatment enough to eliminate CV risk linked with atherogenic dyslipideamia?
Professor C. Vlachopoulos (Athens, GR)
Slides
Presentation thumbnail
How can we improve compliance in patients with atherogenic dyslipidaemia?
Professor M. Hermans (Brussels, BE)
Slides
Presentation thumbnail
Conclusion - Combination therapy in dyslipidaemia. What is new in Europe?
Slides

Access the full session

Session thumbnail
Combination therapy in dyslipidaemia. What is new in Europe?

The Event

Event poster

ESC CONGRESS 2014

2 September 2014 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources